Structure Therapeutics Inc
GPCRHealthcare|Biotechnology|USA
$53.38
-1.79 (-3.25%)
Tangible Book
$20.36
Upcoming Data Readouts (1)
Sep 2026
Est. completion
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2025
P2
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843